Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2024

View source ↗

Summary

PRAC recommended suspending hydroxyprogesterone caproate medicines from the EU market due to safety concerns.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• Hydroxyprogesterone caproate (hydroxyprogesterone caproate)

Snippet

Hydroxyprogesterone caproate medicines to be suspended from the EU market